Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CASP2 | P42575 | 1/20 | 0.46 |
| ▸ | GLP1R | P43220 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24297138 | 0.89 | MEN1 (0.53) | MEN1KMT2ACASP2GLP1RALDH1A1 | |
| SCHEMBL23665087 | 0.86 | KMT2A (0.56) | MEN1KMT2AGLP1R | |
| SCHEMBL10085301 | 0.85 | KMT2A (0.60) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10048529 | 0.85 | CASP2 (0.55) | MEN1KMT2ACASP2HPGD | |
| SCHEMBL12387741 | 0.85 | KMT2A (0.69) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL24700122 | 0.85 | CASP2 (0.44) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL24002279 | 0.85 | KMT2A (0.51) | MEN1KMT2AGLP1RALDH1A1SMN1; SMN2 | |
| SCHEMBL26169621 | 0.85 | KMT2A (0.51) | MEN1KMT2AGLP1RALDH1A1HPGD | |
| SCHEMBL18908665 | 0.84 | KMT2A (0.59) | MEN1KMT2AGLP1RSMN1; SMN2 | |
| SCHEMBL21771221 | 0.84 | KMT2A (0.63) | MEN1KMT2AGLP1RSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140357569-A1 | CYCLOSPORIN CONJUGATES | UCL BUSINESS PLC (GB) | 2014-12-04 | — | — | US | disclosed |
| US-20120157385-A1 | CYCLOSPORIN CONJUGATES | UCL BUSINESS PLC (GB) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157385-A1 | CYCLOSPORIN CONJUGATES | CYP11B1, SHMT2, MRM1 | MEN1 1425/4885KMT2A 3065/4885CASP2 2496/4885 |
| US-20140357569-A1 | CYCLOSPORIN CONJUGATES | CYP11B1, SHMT2, MRM1 | MEN1 1363/4885KMT2A 3078/4885CASP2 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.